Molecular Biomarkers With Potential Clinical Application in Testicular Cancer

被引:3
|
作者
Lobo, Joa [1 ,2 ,3 ]
Acosta, Andres M. [4 ]
Netto, George J. [5 ]
机构
[1] Portuguese Oncol Inst Porto IPO Porto, Prto Comprehens Canc Ctr Raquel Seruca P CCC, Dept Pathol, Porto, Portugal
[2] Portuguese Oncol Inst Porto IPO Porto, Porto Comprehens Canc Ctr, Raquel Seruca & RISE CI IPOP, Canc Biol & Epigenet Grp,IPO Porto Res Ctr GEBC CI, Porto, Portugal
[3] Univ Porto, Dept Pathol & Mol Immunol, ICBAS Esch Med & Biomed Sci, Porto, Portugal
[4] Indiana Univ, Dept Pathol, Indianapolis, IN USA
[5] Univ Alabama Birmingham, Heersink Sch Med, Birmingham, AL 35294 USA
关键词
biomarkers; germ cell tumors; liquid biopsies; molecular pathology; sex cord-stromal tumors; testicular cancer; GERM-CELL TUMORS; CORD-STROMAL TUMORS; OF-THE-LITERATURE; CLINICOPATHOLOGICAL ANALYSIS; INTERNATIONAL SOCIETY; MICRORNA MIR-371A-3P; NUCLEAR-LOCALIZATION; SERUM BIOMARKERS; BETA-CATENIN; TESTIS;
D O I
10.1016/j.modpat.2023.100307
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Testicular germ cell tumors (TGCTs) and sex cord-stromal tumors (SCSTs) are the most common testicular neoplasms. The morphologic spectrum of such tumors is wide, with several histologic subtypes within each group. Testicular tumors often represent a diagnostic challenge, requiring proper identification of their biologic potential for accurate risk stratification and selection of therapy. In the era of precision medicine, molecular biomarkers are increasingly assuming a critical role in the management of patients with cancer. Given the overall rarity of certain types of testicular neoplasms, progress in biomarker research has been relatively slow. However, in recent years, we have witnessed a multitude of important contributions, including both tissue-based and liquid biopsy biomarkers, stemming from important discoveries of tumor pathobiology, accurate histopathological analysis, multi-institutional studies, and genome-wide molecular analyses of specific tumor subtypes. In this review, we provide an overview of the progress in molecular biomarkers of TGCTs and SCSTs, focusing on those with greatest potential for clinical application. In TGCTs, developmental biology has been the key to understanding these tumors and identifying clinically useful biomarkers (from classical serum tumor markers to pluripotency factors and circulating microRNAs of the 371-373 cluster). For SCSTs, studies have focused on tissue biomarkers only, and genome-wide investigations have recently contributed to a better understanding of rare phenotypes and the aggressive biological behavior of some tumors within this nosologic category. Several new biomarkers are moving toward clinical implementation in this field. Therefore, the practicing pathologist should be aware of their strengths and limitations in order to utilize them properly and maximize their clinical benefits. & COPY; 2023 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights reserved.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Molecular biomarkers in prostate cancer tumorigenesis and clinical relevance
    Alqualo, Nathalia Oliveira
    Campos-Fernandez, Esther
    Picolo, Bianca Uliana
    Ferreira, Emanuelle Lorrayne
    Henriques, Laila Machado
    Lorenti, Sabrina
    Moreira, Danilo Caixeta
    Simiao, Maria Paula Silva
    Oliveira, Luciana Beatriz Tiago
    Alonso-Goulart, Vivian
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 194
  • [22] Clinical Advances in Molecular Biomarkers for Cancer Diagnosis and Therapy
    Sethi, Seema
    Ali, Shadan
    Philip, Philip A.
    Sarkar, Fazlul H.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (07): : 14771 - 14784
  • [23] Incorporating molecular biomarkers into clinical practice for gastric cancer
    Nakamura, Shunsuke
    Kanda, Mitsuro
    Kodera, Yasuhiro
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (09) : 757 - 771
  • [24] Biochemical and molecular alterations and potential clinical applications of biomarkers in keratoconus
    Lalgudi, Vaitheeswaran G.
    Shetty, Rohit
    Nischal, Kanwal K.
    Ziai, Setareh
    Koaik, Mona
    Sethu, Swaminathan
    SAUDI JOURNAL OF OPHTHALMOLOGY, 2022, 36 (01) : 7 - 16
  • [25] Recent developments in the clinical application of thyroid cancer biomarkers
    Shibru, Daniel
    Chung, Ki-Wook
    Kebebew, Electron
    CURRENT OPINION IN ONCOLOGY, 2008, 20 (01) : 13 - 18
  • [26] Molecular biomarkers as potential targets for therapeutic strategies in human testicular germ cell tumors: An overview
    Chieffi, Paolo
    Chieffi, Sergio
    JOURNAL OF CELLULAR PHYSIOLOGY, 2013, 228 (08) : 1641 - 1646
  • [27] Molecular pathways and potential biomarkers in gallbladder cancer: A comprehensive review
    Montalvo-Jave, Eduardo E.
    Rahnemai-Azar, Amir A.
    Papaconstantinou, Dimitrios
    Espejel Deloiza, Mariana
    Tsilimigras, Diamantis I.
    Moris, Dimitrios
    Mendoza-Barrera, German Eduardo
    Weber, Sharon M.
    Pawlik, Timothy M.
    SURGICAL ONCOLOGY-OXFORD, 2019, 31 : 83 - 89
  • [28] MUC Glycoproteins: Potential Biomarkers and Molecular Targets for Cancer Therapy
    Ratan, Chameli
    Cicily, Dalia K. D.
    Nair, Bhagyalakshmi
    Nath, Lekshmi R.
    CURRENT CANCER DRUG TARGETS, 2021, 21 (02) : 132 - 152
  • [29] Trifluoperazine as a potential antimetastatic agent in human cancer - From molecular biology to clinical application
    Linxweiler, Maximilian
    Bochen, Florian
    Zimmermann, Richard
    Greiner, Markus
    Koerbel, Christina
    Menger, Michael D.
    Schick, Bernhard
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2016, 38 : S15 - S15
  • [30] Proteomic Serum Biomarkers and Their Potential Application in Cancer Screening Programs
    Huijbers, Anouck
    Velstra, Berit
    Dekker, Tim J. A.
    Mesker, Wilma E.
    van der Burgt, Yuri E. M.
    Mertens, Bart J.
    Deelder, Andre M.
    Tollenaar, Rob A. E. M.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2010, 11 (11) : 4175 - 4193